The proportion of patients achieving NASH resolution in the absence of fibrosis progression was 40%, 36%, and 59% for the 0.1, 0.2, and 0.4 mg semaglutide arms, respectively, whereas the corresponding rate in the placebo arm was 17% ( Notably, based on the results from part 1 of the ESSENCE trial, on 15 August 2025, the FDA approved semaglutide 2.4 mg for the treatment of adults with MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)
The most challenging transition for most people is the jump from 0.25 mg to 0.5 mg because it is the first time the body encounters a dose that significantly affects gastric emptying
Draw volume by vial strength the 2.5 mg starting dose To pull the numbers for any dose on the ladder against your own vial size, use the dosage calculator rather than doing it by hand
Alongside weight reduction, the drug has been shown to improve metabolic health markers, including blood sugar control, hemoglobin A1c, blood pressure, and insulin sensitivity
.png)
